leucylphenylalanine, and leukocyte-derived chemotactic factor as the standard chemoattractants. Based upon statistical analysis of chemotaxis assays, most carried out on at least two and often three or more separate occasions, 26 of 32 UP patients, 7 of 10 post-UJP patients, and 5 of 8 GJP patients exhibited cellular defects of chemotaxis, whereas only 2 of 23 of the patients with adult periodontitis exhibited depressed chemotaxis. Elevated PMNL chemotaxis was occasionally found in subjects with juvenile periodontitis (2 of 32 with UP and two of eight with GJP); however, it was found in a significant number (10 of 23) of patients with adult periodontitis. In eight of nine UP patients, depressed PMNL chemotaxis was observed before and after periodontal therapy. The results indicate that the PMNL chemotaxis defect observed in juvenile periodontitis is due to a cellassociated defect of long duration. These studies suggest that the PMNL plays a major protective role against periodontal infection and that the cellular chemotactic defects and may predispose subjects to LJP.
Bacteria and bacterial products have been implicated as important etiological agents in the development of gingival and periodontal disease (11, 23, 35, 40, 41, 44, 48) . In the presence of dental plaque, an inflammatory infiltrate is usually present in the gingival tissues, with mononuclear phagocytes, lymphocytes, and polymorphonuclear leukocytes (PMNL) comprising the majority of the infiltrate (37, 38) . Cells of lymphocytic origin predominate in the inflamed connective tissue, but the PMNL comprise about half of the leukocytes in the junctional epithelium, and PMNL are prominent cells in the gingival crevice or periodontal pocket. The total number of PMNL in the junctional epithelium increases with the severity of inflammation (34, 36) . The cell migration to the area may be in response to chemotactic substances elaborated by bacteria directly or substances such as endotoxin and bacterial antigens that activate the complement system and produce chemotactic factors (21, 28) . The gingivitis lesion progresses to an advanced gingivitis lesion which may or may not progress to periodontitis (33) . Conceivably, failures of PMNL chemotactic response in the early stages of gingivitis could lead to more rapid advance of the lesion to destructive periodontitis.
Many disorders of PMNL migration have been identified, including decreased locomotor capability of the cell, lowered response to chemoattractants, and the presence of inhibitors to chemotaxis (10, 26, 49) . Patients with PMNL migration disorders characteristically have increased susceptibility to infections and, of particular interest, there is severe periodontal disease associated with several of these disorders (16, 18, 24, 31) .
Recently, several investigators have demonstrated defective PMNL chemotaxis in a number of patients with periodontosis or localized juvenile periodontitis (LJP), or with rapid, earlyonset periodontitis (3, 5, 12, 20) who otherwise appear healthy. Monocyte chemotaxis in most of these patients is normal (3). The results of these studies implicate both an intrinsic cellular defect of PMNL chemotaxis and serum defects. However, the incidence of humoral inhibitors of chemotaxis in LJP or rapid, early-onset periodontitis is not established.
The present investigation was undertaken to: (i) study the prevalence of a PMNL chemotaxis defect in a large group of LJP patients; (ii) study PMNL chemotaxis in patients with other forms of severe periodontal disease; and (iii) determine if the PMNL chemotaxis defect seen in UP patients is a cell-associated defect or is mediated by humoral factors. The groups consisted of young patients with LJP, adults with a history of UJP, young patients with generalized juvenile periodontitis (GJP), and adults with moderate to severe periodontitis in which the disease was considered clinically consistent with patient age, plaque accumulation, and occlusion. A group consisting of periodontally healthy subjects served as controls. 33 to 56 years. These patients exhibited markedly greater alveolar bone loss in the first molar or incisor region (although bone loss was more generalized than in group I) and often had a history of LJP. In four of the patients in this group, we were able to conclusively document prior existence of UP from radiographs taken in their teenage years.
Group III, GJP patients, exhibited severe alveolar bone loss (>14 teeth and no clear pattern of localization) and were younger than 30 years of age (mean, 21.3; range, 17 to 29) There were eight patients in this group (all female; three Caucasian and five black).
Group IV, the adult periodontitis group, consisted of 23 patients, 11 male and 12 female, who exhibited generalized severe alveolar bone loss with multiple vertical osseous defects; they had a mean age of 41.8 years, with a range of 28 to 62 years. All the patients in this group were Caucasian.
The control group consisted of 85 healthy individuals from laboratory and dental school populations who had no radiographic evidence of bone loss or evidence of periodontal disease other than mild gingivitis. Patients and controls were age and sex matched for most experiments.
Isolation of PMNL and chemotaxis assay. PMNL were isolated and chemotaxis was performed as previously described (46) . Briefly, PMNL were separated from heparinized venous blood by Ficoll-Hypaque centrifugation, washed two times in phosphatebuffered saline, and suspended in Gey balanced salt solution (GIBCO Laboratories, Grand Island, N.Y.) containing 2% bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.) at a concentration of 2.5 x 106 cells/ml. The cell suspension was placed in the upper compartment of a modified Boyden chamber separated by a 5-,um micropore filter (Sartorius Membranfilter GmbH, Gottingham, Federal Republic of Germany). The lower compartment contained either endotoxin-activated serum (EAS), Escherichia coli culture supernatant called bacterial factor (BF), the synthetic chemotactic peptide N-formylmethionylleucylphenylalanine (FMLP), or lymphocyte-derived chemotactic factor, all prepared as previously described (46) . Chemotaxis was evaluated by counting the number of cells that accumulated on the distal surface of the filter after a 60-min incubation. Ten high-power fields (x400) were counted for each filter. Each cell population was tested in triplicate chambers. Statistical significance of the difference between patient and control on any given day was determined by analysis of variance (46) . Most patients were tested on at least two and often three or more separate occasions with two or three different chemotactic agents on each occasion.
Day-to-day variability of absolute values for chemotaxis precluded pooling of patient group data; therefore, nonparametric statistics were applied to evaluate patient population differences as follows: a patient's chemotactic response was graded as depressed (-1) , normal (0), or elevated (+1), based upon the statistical analysis of the comparison with the paired control.
Differences that were not significant at the 5% level were graded as normal. A mean value for the patient response was obtained for each chemotactic agent VOL. 27, 1980 on November 6, 2017 by guest http://iai.asm.org/ Downloaded from tested by averaging the nonparametric grades for that agent tested on several occasions and then the mean value of all agents obtained for each patient. Based upon the overall mean of nonparametric grades +8%, the expected error (see Results), each patient was categorized as depressed, normal, or elevated. All experiments are reported.
Population differences were assessed by using a chisquare analysis by comparing the observed population distribution to the expected population distribution (43) . Thirty-six controls were paired, and their chemotaxis results were compared to assess the accuracy of the assay. The expected population distribution was calculated from the number of statistically significant differences observed when the 18 paired controls were tested with three different chemotactic agents, for a total of 54 paired control tests.
Serum inhibitors of chemotaxis. Cell-directed inhibitor (CDI) is a heat-stable substance which interacts directly and reversibly with PMNL to block chemotaxis (26) . The presence of CDI in serum was evaluated by preincubating isolated PMNL in 100dl of fresh serum for 30 min at 370C. Cells were then diluted to 50 ml with phosphate-buffered saline, centrifuged, suspended in Gey medium as above, and assayed. Normal cells were placed in patient serum to assess CDI activity; autologous serum served as control. Washed cells from patients were placed in normal serum to assess recovery of chemotactic response (26) . Cells in autologous serum served as control. The A, B, and 0 blood types for patient and control were matched for these experiments to minimize the potential for agglutination of PMNL. Checkerboard experiments. The effects of various concentrations of chemotactic factor above and below the filter were investigated, using an experimental protocol similar to that described by Zigmond and Hirsch (51). Random migration was studied in the absence of chemotactic factors; chemokinesis was studied when equal concentrations of chemotactic factor were above and below the filter; and chemotaxis was studied when a higher concentration of chemotactic factor was present in the lower compartment. Negative chemotaxis (higher concentration of chemotactic factor in the upper cell compartment) was not studied. All experiments were incubated for 60 min. The leading-front technique (51) was used to quantitate random migration and chemokinesis, since cells do not migrate to the distal surface in 60 min under those conditions. Previous work has demonstrated that the automatic counting techniques we used are comparable to visual measurements (45) . Dose response and kinetics ofthe PMNL chemotaxis defect. The response of LJP patient cells and normal control cells was evaluated at various concentrations of chemotactic factor (EAS) and at various incubation times. The patient and normal cells were always assayed under identical conditions. Effect of therapy on the PMNL chemotaxis defect. PMNL chemotactic response was evaluated after conventional therapy in nine LJP patients. Treatment consisted of repeated scaling and root planing and in some cases antibiotic therapy (2 weeks of tetracycline administration, 1 g/day orally at 6-week intervals for the first 15 months). Chemotaxis was evaluated from 6 months to 2 years after such therapy was initiated. Since tetracycline has been reported to affect PMNL chemotaxis (27) , patients in this series were tested several weeks after the cessation of tetracycline administration.
RESULTS
Control group. The chemotactic response to three different chemotactic agents (EAS, BF, FMLP) was assessed in 18 pairs of control subjects. In all, 54 paired PMNL chemotactic tests were analyzed. Significance of differences at the 95% confidence level was determined by analysis of variance. Nine of the 54 paired control tests were significantly different from each other, and these differences were normally distributed, with four showing elevated chemotaxis and five showing depressed chemotaxis (Fig. 1) . Of the tests that were different, no member of a pair of controls was different with more than one agent at a time, suggesting experimental error rather than true differences between the PMNL. Based upon this analysis, the expected values for the chi-square analysis for population differences were computed, and an experimental error of 8% of the tests showing depressed chemotaxis and 8% of the tests showing elevated chemotaxis was established.
Group I. The PMNL chemotaxis of the LJP patients was compared, on a day-to-day-basis, with that of periodontally normal, healthy, age- (Fig. 2) . There was no difference in the percentage of defective subjects when tested with different chemotactic agents; however, chemotactic depression was most consistently observed with EAS.
Of the 26 UP patients who are described as having depressed chemotaxis, 8 were depressed to all agents every time they were tested. The others were depressed a majority of times tested but did test normal to individual agents occasionally (Fig. 3) .
The IUP group was 60% black, whereas the control group was >95% Caucasian. To assess the possibility of racial differences accounting for the observed distribution of PMNL chemotaxis defects, the two racial groups were analyzed separately. Chi-square analysis indicated that there was no relationship between race and PMNL chemotaxis (P > 0.05) for this group of subjects.
It is interesting to note that two patients with UP had an elevated chemotactic response. One of these patients, a 22-year-old female, was tested four times with three different agents against four different control subjects over an 8-month period. The (Fig. 4) Group m. Figure 4 shows the PMNL chemotactic response of the eight GJP patients. Five of the eight patients showed depressed chemotaxis, one tested normal, and two showed elevated chemotaxis. Group IV. Eleven of the 23 patients in the adult periodontitis group were normal, and two showed depressed chemotaxis. However, a significant number (P < 0.001) of patients in this group exhibited elevated chemotaxis (Fig. 5) . Of the 10 patients that exhibited elevated chemotaxis, 4 were tested on 6 or 7 separate days over an 8-month period both before and during periodontal therapy. The number of elevated tests to individual agents exhibited by each patient over this period of time was significant (P < 0.05) and did not appear to relate to periodontal disease status. Other elevated patients in this group, although tested fewer times, showed consistent elevation of PMNL chemotaxis.
Serum effects on PMNL chemotaxis. CDI was found in the serum of 4 of 21 randomly selected UP patients with chemotaxis defects (P > 0.05). UP patient cells did not recover activity in normal serum.
Checkerboard experiment. The checkerboard experiment compared six randomly selected UP patients with six separate controls, and depression of chemotaxis of the LJP patients' neutrophils was observed. The random migration of LJP PMNL was the same as for controls, and the chemotaxis defect was apparent at all chemotactic factor concentrations tested ( Table 2) .
Characterization of the PMNL chemotaxis defect. The depressed chemotactic response of an LJP patient was observed at incubation times ranging from 30 to 120 min (Fig. 6) . The dose-response behavior of the same patient's PMNL to EAS was evaluated, and depressed chemotaxis was observed at all concentrations tested. Similar results were obtained on six randomly selected LJP patients compared with normal controls.
Of the 26 UJP patients exhibiting depressed PMNL chemotaxis, 9 were tested both before and after conventional therapy to determine whether the disease state was causing PMNL dysfunction or whether the PMNL migration defect was independent of disease status. The chemotaxis defect persisted after therapy in eight of the nine patients tested (P < 0.001; Table 3 ). (6) and hyperimmunoglobulinemia E (7, 15) indicate an intrinsic cellular defect in which humoral factors appear to have no role. In some diseases where the intrinsic cellular defect is permanent, such as Chediak-Higashi syndrome (4), random migration is normal. In other conditions of intrinsic cellular defects, such as measles (1) or hypovitaminosis D (rickets) (24) , random migration is also defective, implying a generalized locomotion defect which is reflected in chemotaxis rather than a specific defect in the directional response to chemotactic agents.
Study of the serum of cirrhotic patients (8, 25) revealed a cell-directed inhibitor of chemotaxis which reversibly binds to PMNL. This naturally occurring factor is characterized by its effect on normal cells and the ability of neutrophils from cirrhotic patients to recover normal activity in normal serum. This factor may be in excess in serum, or its natural antagonist may be deficient (42, 45) . In studies where the antagonist is deficient, normal plasma added to the deficient PMNL will correct the defect, but patient serum or plasma has no effect on normal cells. Another type of serum inhibitor has been described that inactivates chemotactic factors from complement or bacteria (2, 49, 50) (CFI). There is also evidence of natural inhibitors to these chemotactic factor inactivators (47) .
The present studies of UP patients revealed that the defect was detected when the PMNL were tested in a serum-free system. Additionally, patient serum had no effect on normal cells in 81% of the cases tested, and patient cells did not recover chemotactic activity when incubated in normal serum. This evidence strongly suggests that there is an intrinsic PMNL defect in chemotaxis and that for most patients CDIs do not contribute to the PMNL chemotaxis defect.
The presence of humoral inhibitors was reported in two earlier studies, although the incidence of these inhibitors differed somewhat. (20) found that 2 of 14 UP patients had CDI, 1 of 14 had CFI, and 1 of 14 had reduced chemotactic factor generation.
Further evidence as to the nature of the chemotaxis defect was obtained from the study of post-LJP patients. The finding of a PMNL chemotaxis defect in these patients in the absence of CDI provides indirect evidence that the chemotaxis defect observed in LIP patients persists for many years. This concept is further supported by the fact that treatment of the disease did not reverse the defect in 91% of the cases treated. These data suggest that the chemotactic defect in LIP patients is not cell associated and long lasting.
We have demonstrated PMNL chemotaxis defects in periodontal disease-free younger siblings of LIP patients, suggesting that the chemotaxis defect is familial and may precede overt disease. If this is indeed the case, the neutrophil dysfunction may predispose or increase susceptibility to LIP (L. J. Cianciola, R. J. Genco, M. R. Patters, and J. McKenna, Am. Assoc. Dent. Res. Abstr., 1977) . Genetic determination of neutrophil chemotaxis defects has been described in several instances, for example, in the family described by Niethammer et al. (32) in which depressed neutrophil chemotaxis was inherited as an autosomal recessive characteristic.
Random migration as measured by the checkerboard experiments (Table 2) show that this parameter is normal in LIP patients. This information plus the chemotaxis data suggest that the defect is one of directed migration, namely, the inability to respond to a chemotactic gradient. In addition, the kinetic and dose-response data (Fig. 6) The study of PMNL chemotaxis defects in humans may be limited by illness or death of the patient. The UP group is an excellent group for the study of cell-associated cellular defects of chemotaxis and may aid in the further description of the mechanisms of cell movement, since the patients appear to be healthy except for the periodontal disease, and the PMNL defect appears to be of long duration. This study and others (3, 5, 11, 19) suggest that the PMNL contributes to more severe disease.
